Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$78.79 USD

78.79
1,176,066

-2.13 (-2.63%)

Updated Nov 26, 2021 01:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.42%
2Buy19.05%
3Hold10.68%
4Sell6.41%
5Strong Sell3.08%
S&P50011.42%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for CRSP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 1,690 944 457 240 316
Receivables 0 0 0 3 3
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 26 44 10 6 2
Total Current Assets 1,717 988 466 248 320
Net Property & Equipment 42 31 19 19 21
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 18 6 4 4 3
Total Assets 1,828 1,067 489 271 345
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 9 6 5 2 5
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 64 31 21 12 16
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 10 12 1 1 1
Total Current Liabilities 94 57 28 15 22
Mortgages 0 0 0 0 0
Deferred Taxes/Income 12 12 58 57 78
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 8 14 11 12 12
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 164 127 97 84 112
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2 2 2 1 1
Capital Surplus 2,236 1,162 682 312 289
Retained Earnings -574 -225 -292 -125 -57
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,664 939 392 188 233
Total Liabilities & Shareholder's Equity 1,828 1,067 489 271 345
Total Common Equity 1,664 939 392 188 233
Shares Outstanding 71.20 55.20 51.90 45.80 39.80
Book Value Per Share 23.37 17.02 7.56 4.10 5.85

Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.

All items in Millions except Per Share data.

9/30/2021 6/30/2021 3/31/2021 12/31/2020 9/30/2020
Assets          
Cash & Equivalents 2,477 2,589 1,806 1,690 1,366
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 41 31 26 26 25
Total Current Assets 2,519 2,621 1,832 1,717 1,391
Net Property & Equipment 106 75 52 42 38
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 22 24 23 18 18
Total Assets 2,822 2,900 1,958 1,828 1,485
Liabilities & Shareholders Equity 9/30/2021 6/30/2021 3/31/2021 12/31/2020 9/30/2020
Notes Payable 0 0 0 0 0
Accounts Payable 10 10 13 9 19
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 72 72 53 64 42
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 2 2 5 10 13
Total Current Liabilities 96 100 83 94 84
Mortgages 0 0 0 0 0
Deferred Taxes/Income 12 12 12 12 12
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 8 8 8 7
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 309 296 152 164 142
Shareholders Equity 9/30/2021 6/30/2021 3/31/2021 12/31/2020 9/30/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2 2 2 2 2
Capital Surplus 2,566 2,530 2,490 2,236 1,808
Retained Earnings -55 72 -687 -574 -467
Other Equity -1 -1 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 2,513 2,604 1,806 1,664 1,343
Total Liabilities & Shareholder's Equity 2,822 2,900 1,958 1,828 1,485
Total Common Equity 2,513 2,604 1,806 1,664 1,343
Shares Outstanding 76.20 76.20 75.70 71.20 70.60
Book Value Per Share 32.98 34.17 23.85 23.37 19.03